Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict sudden cardiac death after a heart attack? new study aims to find out

NCT ID NCT07545512

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 400 people who had a heart attack and have moderately reduced heart function (ejection fraction 35-50%). Participants will get a small implantable heart monitor to track their heart rhythm for up to 5 years. The goal is to identify markers that could predict who is at risk of sudden cardiac death, so doctors can better decide who needs a defibrillator.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better tools to predict who is at risk of sudden cardiac death after a heart attack, helping doctors decide who needs a defibrillator.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear markers, and results may not change practice for years. The implantable monitor carries small risks like infection or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years of age * Hospitalized for acute STEMI within 6 months (Type 1 myocardial infarction according to ESC recommendations, Thygesen EHJ 2018). * Left ventricular ejection fraction between 35% and 50% at least 40 days after acute myocardial infarction (see above). * Under optimal tolerated medical treatment. * Covered by a social security scheme. * Legally competent to give voluntary informed consent to participate in the study. * Patient who will not participate in further studies involving an investigational drug or device until the end of the trial (i.e. 60 months). Participation in registries is authorized Exclusion Criteria: * Presence of a secondary prevention indication for implantation of an implantable automatic defibrillator (ICD) * Presence of a pacemaker * Administration of ventricular antiarrhythmic drugs other than beta-blockers (i.e. amiodarone, sotalol, flecainide) * Patients with systemic diseases (cancer, liver failure or end-stage renal disease) * Patients with assessed life expectancy \< 1 year. * Age \> 80 * Adult patient under legal protection (guardianship, curatorship or other legal protection measure) * The subject is pregnant or nursing or positive beta HCG for women of childbearing age * Patient participating in another clinical research protocol involving an investigational drug or device within the last 30 days (participation in a registry is permitted at the same time).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction (MI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myocardial infarction sudden arrhythmia death syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction (MI) Sudden cardiac death due to cardiac arrhythmia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP - Hôpital européen Georges-Pompidou

    Paris, France

  • CH Vichy

    Vichy, France

  • CHU Amiens

    Amiens, France

  • CHU Brest

    Brest, France

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63000, France

  • CHU Nancy

    Nancy, France

  • CHU Saint Etienne

    Saint-Etienne, France

  • CHU Toulouse

    Toulouse, France

  • HCL - Hôpital Pierre Wertheimer

    Lyon, France

  • HCL - Hôpital de la Croix-Rousse

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.